Scarica l'app Stockscreener
57.50
0.58%
0.33
Dopo l'orario di chiusura:
57.50
Precedente Chiudi:
$57.17
Aprire:
$57.46
Volume 24 ore:
1.38M
Relative Volume:
0.70
Capitalizzazione di mercato:
$11.02B
Reddito:
$2.95B
Utile/perdita netta:
$523.88M
Rapporto P/E:
21.38
EPS:
2.69
Flusso di cassa netto:
$620.18M
1 W Prestazione:
+6.28%
1M Prestazione:
+1.25%
6M Prestazione:
-13.96%
1 anno Prestazione:
-28.99%
Intervallo 1D:
$57.03
$58.07
Intervallo di 1 settimana:
$53.98
$58.07
Portata 52W:
$52.93
$94.85
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Nome
Biomarin Pharmaceutical Inc
Settore
Industria
Telefono
(415) 506-6700
Indirizzo
105 DIGITAL DRIVE, NOVATO, CA
Confronta BMRN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
57.50 | 11.02B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-24 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-30 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-20 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Iniziato | Evercore ISI | Outperform |
| 2023-11-15 | Iniziato | Wells Fargo | Overweight |
| 2023-10-23 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Iniziato | Raymond James | Mkt Perform |
| 2023-09-18 | Iniziato | UBS | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-07-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2023-02-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Iniziato | Citigroup | Neutral |
| 2023-01-30 | Iniziato | BMO Capital Markets | Market Perform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2022-10-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Ripresa | Wedbush | Neutral |
| 2022-04-25 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-09-09 | Aggiornamento | Stifel | Hold → Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-04 | Ripresa | Guggenheim | Buy |
| 2021-03-01 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Downgrade | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Downgrade | Stifel | Buy → Hold |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Reiterato | Citigroup | Buy |
| 2020-01-28 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-27 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-24 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-04-09 | Ripresa | Raymond James | Outperform |
| 2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Reiterato | Stifel | Buy |
| 2018-08-03 | Reiterato | Stifel | Buy |
Mostra tutto
Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie
BioMarin Generates Patient Experience Data With Early And Often Engagement - Clinical Leader
Jim Cramer on BioMarin: “I Don’t Think It Works Now” - MSN
BioMarin’s SWOT analysis: stock growth potential amid rare disease focus - Investing.com
BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz - MSN
Jim Cramer Discussed These 16 Stocks Recently - Insider Monkey
Phenylktonuria Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Erytech Pharma SA, Homology Medicines Inc., Synlogic Inc., BioMarin Pharmaceuticals - Barchart.com
Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs - Benzinga
Morquio Syndrome (MPS-IV) Drug Market Is Booming So Rapidly - openPR.com
Here Are All 6 Stocks I've Bought Through 5 Months of 2025 - The Motley Fool
The Top 12 Companies Hiring in Biopharma Now - BioSpace
Marin Awareness Walk Draws Over 100 Community Members - Patch
inozyme pharma announces executive bonuses amid merger plans By Investing.com - Investing.com Nigeria
inozyme pharma announces executive bonuses amid merger plans - Investing.com
BioMarin Now Targets $3 Bln Revenue Goal For 2025 - RTTNews
The past five years for BioMarin Pharmaceutical (NASDAQ:BMRN) investors has not been profitable - simplywall.st
Is the Options Market Predicting a Spike in BioMarin Pharmaceutical Stock? - MSN
Is The Options Market Predicting A Spike In BioMarin Pharmaceutical Stock? - Barchart.com
Noonan Syndrome Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | Novo Nordisk A/S, BioMarin Pharma - The Globe and Mail
FDA issues BioMarin complete response letter for Duchenne muscular dystrophy drug Kyndrisa - FirstWord Pharma
Stifel maintains Buy on BioMarin, price target at $91 By Investing.com - Investing.com India
Stifel maintains Buy on BioMarin, price target at $91 - Investing.com
Phenylktonuria Treatment Market Overall Study Report - openPR.com
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - Yahoo Finance
BioMarin’s SWOT analysis: genetic medicine firm’s stock shows growth potential - Investing.com
Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More - MSN
Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens - MSN
Rx Rundown: BioMarin, Novavax, CellCentric and more - Medical Marketing and Media
BioMarin Pharmaceutical Approves Equity Plan Amendment - TipRanks
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio - Yahoo
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), ACADIA Pharmaceuticals (ACAD) and Quanterix (QTRX) - The Globe and Mail
BioMarin’s Acquisition of Inozyme Pharma - Global Legal Chronicle
INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc.INZY - Business Wire
6,941 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Acquired by Focus Partners Wealth - Defense World
BioMarin agrees to acquire Inozyme for $270m - MSN
Insider Sell Alert: Erin Burkhart Sells Shares of Biomarin Pharmaceutical Inc (BMRN) - GuruFocus
Is this European biotech’s moment? — a BioCentury podcast - biocentury.com
BioMarin Expands Rare Disease Portfolio with $270M Inozyme Acquisition - MSN
BioMarin to buy enzyme therapy developer Inozyme in $270M all-cash deal - MSN
Inozyme Pharma finds buyer in BioMarin after strategic review - The Business Journals
Bernstein raises BioMarin stock target to $95, maintains Outperform - Investing.com Australia
Bernstein raises BioMarin stock target to $95, maintains Outperform By Investing.com - Investing.com Nigeria
BioMarin: Inozyme Acquisition Falls Short Of Offsetting Looming Revenue Risks (Downgrade) - Seeking Alpha
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
BioMarin Buying Inozyme Pharma In $270 Million Deal - Pulse 2.0
StockWatch: With Inozyme Buyout, BioMarin Pursues Growth via M&A - Genetic Engineering and Biotechnology News
Biomarin Pharmaceutical Inc Azioni (BMRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.68%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):